Refractory Chronic Lymphocytic Leukemia (CLL)

Refractory Chronic Lymphocytic Leukemia (CLL) is the indication for 5 drugs in DrugBank. It is covered by 5 curated, structured indications.

Also known as: refractory CLL · Chronic lymphocytic leukemia refractory · Refractory Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia (CLL) - Refractory · Chronic Lymphocytic Leukaemia Refractory
Classified under: Hemic and Lymphatic Diseases
Immune System Diseases
Neoplasms
Indicated drugs: Duvelisib
Lenalidomide
Lisocabtagene maraleucel
Ofatumumab
Pirtobrutinib

Resolves to

Vocabularies

MedDRA10008962UMLSC0278791

What you can answer from here — as of October 24, 2026

5Indicated drugsWith each drug's targets and mechanism

Listed above

5Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

181Clinical trialsPhase, status and sponsor resolved per trial

2Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Refractory Chronic Lymphocytic Leukemia (CLL) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.